Clembu-K 40 - Kassel Pharma

Clenbuterol hydrochloride first gained approval in Europe and Latin America as a long-acting beta-2 agonist, developed for the treatment of bronchial conditions such as asthma. Its appeal lay in its ability to stimulate bronchodilation without significantly raising heart rate or blood pressure, a key concern with older compounds. In contrast to its global presence, the drug was never approved for human use in the United States, due to commercial redundancy rather than medical limitations.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Clembu-K 40 by Kassel Pharma, consult with your doctor or healthcare professional.